Abstract:Rationale: Triple-negative breast cancer (TNBC) does not respond to anti-estrogen and anti-HER2 therapies and is commonly treated by chemotherapy. TNBC has a high recurrence rate, particularly within the first 3 years. Thus, there is an urgent clinical need to develop more effective therapies for TNBC. Topoisomerase I (TOP1) inhibitors cause DNA damage, making these drugs desirable for TNBC treatment since DNA repair machinery is defective in this subtype of breast cancer. Among the main molecular subtypes of breast cancer, the TNBC cell lines exhibited the highest TOP1 inhibition sensitivity. However, clinically used TOP1 inhibitors, such as topotecan and irinotecan, have shown limited clinical applications and the reasons remain unclear. Understanding the mechanism of differential responses to TOP1 blockade and identifying the predictive markers for cancer cell sensitivity will help further TOP1-targeted therapy for TNBC treatment and improve the clinical use of TOP1 inhibitors. Methods: Viability assays were used to evaluate breast cancer cell sensitivity to topotecan and other TOP1 inhibitors as well as TOP2 inhibitors. An in vitro-derived topotecan-resistant TNBC cell model and TNBC xenograft models were employed to confirm cancer cell response to TOP1 blockade. RNA-seq was used to identify potential predictive markers for TNBC cell response to TOP1 blockade. Western blotting and qRT-PCR were performed to measure the protein levels and RNA expression. ATAC-seq and luciferase reporter assays were used to examine MYC transcriptional regulations. The effects of MYC and JNK in cancer cell response to TOP1 inhibition were validated via loss-of-function and gain-of-function experiments. Results: We observed two distinct and diverging cancer cell responses - sensitive versus resistant to TOP1 inhibition, which was confirmed by TNBC xenograft mouse models treated by topotecan. TNBC cells exhibited bifurcated temporal patterns of ATR pathway activation upon TOP1 inhibitor treatment. The sensitive TNBC cells showed an "up then down" dynamic pattern of ATR/Chk1 signaling, while the resistant TNBC cells exhibited a "persistently up" profile. On the contrary, opposite temporal patterns of induced expression of MYC, a key regulator and effector of DNA damage, were found in TNBC cells treated by TOP1 inhibitors. Mechanistically, we showed that TOP1-induced JNK signaling upregulated MYC expression. Furthermore, pharmacological inhibition of ATR reversed TNBC cell resistance to topotecan, whereas MYC knockdown and JNK inhibition reduced cancer cell sensitivity. Conclusions: Dynamic temporal profiles of induced ATR/Chk1 and JNK activation as well as MYC expression, may predict cancer cell response to TOP1 inhibitors. JNK activation-mediated constitutive elevation of MYC expression may represent a novel mechanism governing cancer cell sensitivity to TOP1-targeting therapy. Our results may provide implications for identifying TNBC patients who might benefit from the treatment with TOP1 inhibitors.

Cyclic AMP-dependent protein kinase type I is involved in hypersensitivity of human breast cells to topoisomerase II inhibitors.

Overexpression of the RI Alpha Subunit of Protein Kinase A Confers Hypersensitivity to Topoisomerase II Inhibitors and 8-Chloro-cyclic Adenosine 3'5'-Monophosphate in Chinese Hamster Ovary Cells.

Relationship Between Expression of Topoisomerase II Isoforms and Intrinsic Sensitivity to Topoisomerase II Inhibitors in Breast Cancer Cell Lines

Altered Drug Interaction and Regulation of Topoisomerase IIbeta: Potential Mechanisms Governing Sensitivity of HL-60 Cells to Amsacrine and Etoposide.

Differential Expression of the Topoisomerase IIα and Β Genes in Human Breast Cancers

Attenuation of Drug-Stimulated Topoisomerase Ii Dna Cleavable Complex Formation in Wild-Type Hl-60 Cells Treated with an Intracellular Calcium Buffer is Correlated with Decreased Cytotoxicity and Site-Specific Hypophosphorylation of Topoisomerase Ii Alpha

Nuclear Topoisomerase II Levels Correlate with the Sensitivity of Mammalian Cells to Intercalating Agents and Epipodophyllotoxins.

Intercalating TOP2 Poisons Attenuate Topoisomerase Action at Higher Concentrations

Differential expression of the topoisomerase II alpha and beta genes in human breast cancers.

Phosphorylation of Serine 1106 in the Catalytic Domain of Topoisomerase IIα Regulates Enzymatic Activity and Drug Sensitivity

Cross-sensitivity to Topoisomerase II Inhibitors in Cytotoxic Drug-Hypersensitive Chinese Hamster Ovary Cell Lines.

Overproduction of topoisomerase II in an ataxia telangiectasia fibroblast cell line: comparison with a topoisomerase II-overproducing hamster cell mutant.

Topotecan-induced Topoisomerase IIalpha Expression Increases the Sensitivity of the CML Cell Line K562 to Subsequent Etoposide Plus Mitoxantrone Treatment.

Response to ICRF-159 in Cell Lines Resistant to Cleavable Complex-Forming Topoisomerase II Inhibitors.

P5-13-13: the Role of Topoisomerase IIa in Predicting Sensitivity to Anthracyclines in Breast Cancer Patients: A Meta-Analysis of Published Literatures.

The Role of Topoisomerase IIα in Predicting Sensitivity to Anthracyclines in Breast Cancer Patients: a Meta-Analysis of Published Literatures

Topoisomerase I and II Inhibitors Control Caspase-2 Pre-Messenger RNA Splicing in Human Cells

Resistance to topoisomerase poisons due to loss of DNA mismatch repair

The Role Of Topoisomerase Ii Alpha In Predicting Sensitivity To Anthracyclines In Breast Cancer Patients: A Meta-Analysis Of Published Literatures

TOP1 Inhibition Induces Bifurcated JNK/MYC Signaling That Dictates Cancer Cell Sensitivity.

The Topoisomerase II Catalytic Inhibitor ICRF-193 Preferentially Targets Telomeres That Are Capped by TRF2.